- Home
- GEVO vs FULC Comparison
GEVO vs FULC Comparison
Compare GEVO & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEVO
- FULC
- Stock Information
- Founded
- GEVO 2005
- FULC 2015
- Country
- GEVO United States
- FULC United States
- Employees
- GEVO N/A
- FULC 45
- Industry
- GEVO Major Chemicals
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- GEVO Industrials
- FULC Health Care
- Exchange
- GEVO Nasdaq
- FULC Nasdaq
- Market Cap
- GEVO 498.2M
- FULC 468.1M
- IPO Year
- GEVO 2011
- FULC 2019
- Fundamental
- Price
- GEVO $1.91
- FULC $9.67
- Analyst Decision
- GEVO Buy
- FULC Buy
- Analyst Count
- GEVO 2
- FULC 7
- Target Price
- GEVO $8.13
- FULC $10.43
- AVG Volume (30 Days)
- GEVO 4.3M
- FULC 677.9K
- Earning Date
- GEVO 11-10-2025
- FULC 10-29-2025
- Dividend Yield
- GEVO N/A
- FULC N/A
- EPS Growth
- GEVO N/A
- FULC N/A
- EPS
- GEVO N/A
- FULC N/A
- Revenue
- GEVO $120,932,000.00
- FULC N/A
- Revenue This Year
- GEVO $909.99
- FULC N/A
- Revenue Next Year
- GEVO $11.14
- FULC N/A
- P/E Ratio
- GEVO N/A
- FULC N/A
- Revenue Growth
- GEVO 675.75
- FULC 2752.05
- 52 Week Low
- GEVO $0.92
- FULC $2.32
- 52 Week High
- GEVO $2.98
- FULC $10.11
- Technical
- Relative Strength Index (RSI)
- GEVO 36.43
- FULC 60.42
- Support Level
- GEVO $1.83
- FULC $7.51
- Resistance Level
- GEVO $2.27
- FULC $9.05
- Average True Range (ATR)
- GEVO 0.14
- FULC 0.84
- MACD
- GEVO -0.05
- FULC 0.05
- Stochastic Oscillator
- GEVO 13.89
- FULC 86.39
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.